Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) was founded on January 11, 2008 and is headquartered in Cambridge, Massachusetts, USA, with 82 full-time employees (6/30/2019). It is a clinical-stage biopharmaceutical company. Utilize the company’s expertise in epigenetics to discover and develop new treatments to address the serious unmet medical needs in cancer diseases related to abnormal gene expression or drug resistance.
Constellation Pharmaceuticals (CNST):
Constellation Pharmaceuticals’ comprehensive epigenetics platform enables it to validate targets and produce small molecules against these targets, which selectively regulate gene expression in tumors and immune cells to drive anti-tumor activity. Platform insights and clinical experience guide the development of the company’s wholly-owned main product candidates:
1. CPI-1205, an enhancer that inhibits zeste homolog 2 (EZH2), is currently undergoing multiple clinical trials, including: Phase I/II clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Test; a test used in conjunction with an androgen receptor signaling inhibitor, which the company calls the ProSTAR test.
2. CPI-0610 inhibits bromodomain and extra terminal domain (BET) proteins, and is currently in phase II clinical trials as a monotherapy for myelofibrosis (MF), and combined with ruxolitinib (sold as Jakafi®) to treat bone marrow Clinical trials of fibrosis.
Constellation Pharmaceuticals Inc. believes that the company’s methods for targeting these central gene regulatory mechanisms related to cancer proliferation can enable it to provide treatment assistance to cancer patients.
Constellation Pharmaceuticals retains the global development and commercial rights of all candidate products. The company’s goal is to become a fully integrated biopharmaceutical company that can commercialize its products. The management team of Constellation Pharmaceuticals has extensive experience in the discovery, development, regulatory and commercialization of cancer treatments, including holding senior positions in leading pharmaceutical companies.
Constellation Pharmaceuticals (CNST investment:
Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) submitted its IPO prospectus on 6/22/2018 and listed on Nasdaq on 7/19/2018 with an issue price of US$15.00. It issued 5.34 million shares and raised 8010. Ten thousand dollars, joint underwriting by JP Morgan / Jefferies / BMO Capital Markets . On the first day of listing, it broke substantially.